Pemafibrate was reported to reduce ALT in non-alcoholic fatty liver disease (NAFLD) patients, but efficacy was not clearly elucidated due to the small size of previous study populations. This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.